SOUTH SAN FRANCISCO, Calif.
Dec. 5, 2011
/PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected
diagnostic products addressing unmet needs in cardiovascular disease, today said that it plans to present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference on
Tuesday, December 6, 2010
11:00 am Pacific Time
2:00 pm Eastern Time
) at the St. Regis Hotel in
San Francisco, CA.
Brian E. Ward
, Ph.D., Chief Executive Officer of diaDexus, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto diaDexus' website at
About diaDexus, Inc.
diaDexus, Inc., based in
South San Francisco, California
, is focused on the development and commercialization of patent-protected
diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC ELISA Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. For more information, please visit the company's website at
Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
SOURCE diaDexus, Inc.